Inaugural Kure It!
Networking Cruise & Poker Run
benefitting City of Hope

Kureit Networking Cruise and Poker Run

Join us on July 16th at the Balboa Bay Club following the CSSA Owner's Summit for a fun 1-hour networking cruise on the water of the beautiful Newport Bay. Enjoy friendly competition, appetizers, drinks, and a great networking opportunity — all while raising money for cancer research.

For sponsorship and other details please call 949-482-7081 or click to view and download.

For more information on the 5th Annual CSSA Owner's Summit please visit the CSSA web site.

How you can make a difference

Interesting Fact:

While melanoma has a slightly higher incidence rate than kidney cancer (59,940 v. 51,190) and lower mortality rate (14% v. 25%), the National Cancer Institute provides over three times as much funding for melanoma research than it does for kidney cancer research ($97,199,000 v. $31,055,000).

(Sources: Incidence and Mortality estimates for 2007 developed by the American Cancer Society based on incidence data from the NCI's Surveillance, Epidemiology, and End Results Program and on death data from the National Center for Health Statistics, Centers for Disease Control and Prevention. Funding figures based on the Fiscal Year 2006 as reported by the Financial Management Branch of the National Cancer Institute.)

Link to our Facebook page

KureIt! at Facebook

About the Kure It! Kidney Cancer Research Fund

The Kure It! Kidney Cancer Research Fund is a not-for-profit affiliate fund of the City of Hope National Medical Center. Established in the spring of 2007, the Kure It! Kidney Cancer Research Fund is dedicated entirely to funding kidney cancer research under the direction of Dr. Robert Figlin, Associate Director for Clinical Oncology at the City of Hope in Los Angeles. All donations made to the KIKCRF are tax-deductible under Section 501(c)(3) of the Internal Revenue Code.

Incidence and Mortality Rates of Kidney, Breast, Prostate Cancers

When compared to breast and prostate cancer, kidney cancer has the highest mortality rate, despite having the lowest projected incidence. In the U.S. alone, roughly 25% of kidney cancer patients will lose their battle this year as compared to 23% of breast cancer patients and 12% of prostate cancer patients.

Mortality Ratios for Prostate, Breast, Melanoma & Kidney Cancers

graph of selected cancer mortality rates

And yet, kidney cancer receives approximately 1/17 of the amount of funding as breast cancer and only 1/10 the amount as prostate cancer.

Federal Funding for Prostate, Breast, Melanoma & Kidney Cancers

graph of funding for selected cancers
/r